Sites and mechanisms of action of melatonin in mammals: The MT1 and MT2 receptors;Sites et mécanismes d'action de la mélatonine chez les mammifères: Les récepteurs MT1 et MT2

Journal de la Societe de Biologie

Volumn 201, Issue 1, 2007, Pages 85-96

  Schuster, Carole ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; CIRCADIAN RHYTHM; CONFERENCE PAPER; MAMMAL; PERIODICITY; PHYSIOLOGY; RETINA; SEASON;

ACTIVITY CYCLES; ANIMALS; CIRCADIAN RHYTHM; LIGANDS; MAMMALS; MELATONIN; MODELS, BIOLOGICAL; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RETINA; SEASONS;

MAMMALIA;

EID: 34548456054     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2007010     Document Type: Conference Paper

References (85)

1. Armstrong S. M., McNulty O. M., Guardiola-Lemaitre B. & Redman J. R., Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav., 1993, 46, 45-49.
2. Audinot V., Mailliet F., Lahaye-Brasseur C., Bonnaud A., Le Gall A., Amosse C., Dromaint S., Rodriguez M., Nagel N., Galizzi J. P., Malpaux B., Guillaumet G., Lesieur D., Lefoulon F., Renard P., Delagrange P. & Boutin J. A., New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367, 553-561.
3. Ayoub M. A., Couturier C., Lucas-Meunier E., Angers S., Fossier P., Bouvier M. & Jockers R., Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem., 2002, 277, 21522-21528.
4. Ayoub M. A., Levoye A., Delagrange P. & Jockers R., Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol. Pharmacol., 2004, 66, 312-321.
5. Barrett P., Conway S., Jockers R., Strosberg A. D., Guardiola-Lemaitre B., Delagrange P. & Morgan P. J., Cloning and functional analysis of a polymorphic variant of the ovine Mel 1a melatonin receptor. Biochem. Biophys. Acta, 1997, 1356, 299-307.
6. Barrett P., Morris M., Choi W. S., Ross A. & Morgan P. J., Melatonin receptors and signal transduction mechanisms. Biol. Signals Recept., 1999, 8, 6-14.
7. Blask D. E., Sauer L. A. & Dauchy R. T., Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanism of action and their implications for circadian-based cancer therapy. Curr. Topics Med. Chem., 2002, 2, 113-132.
8. Cassone V. M., Effects of melatonin on vertebrate circadian systems. Trends Neurosci., 1990, 13, 457-464.
9. Clemens J. W., Jarzynka M. J. & Witt-Enderby P. A., Down-regulation of MT1 melatonin receptors in rat ovary following estrogen exposure. Life Sci., 2001, 69, 27-35.
10. Conway S., Canning S. J., Barrett P., Guardiola-Lemaitre B., Delagrange P. & Morgan P. J., The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a β melatonin receptor. Biochem. Biophys. Res. Commun., 1997, 239, 418-423.
11. Conway S., Mowat E. S., Drew J. E., Barrett P., Delagrange P. & Morgan P. J., Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor. Biochem. Biophys. Res. Commun., 2001, 282, 1229-1236.
12. Dardente H., Klosen P., Pévet P. & Masson-Pévet M., MT1 melatonin receptor mRNA expressing cells in the pars tuberalis of the European hamster: effect of photoperiod. J. Neuroendocrinol., 2003a, 15, 778-786.
13. Dardente H., Menet J. S., Poirel V. J., Streicher D., Gauer F., Vivien-Roels B., Klosen P., Pévet P. & Masson-Pévet M., Melatonin induces Cry1 expression in the pars tuberalis of the rat. Mol. Brain Res., 2003b, 114, 101-106.
14. Dubocovich M. L., Melatonin is a potent modulator of dopamine release in the retina. Nature, 1983, 204, 183-184.
15. Dubocovich M. L., Masana M. I., Iacob S. & Sauri D. M., Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch. Pharmacol., 1997, 355, 365-375.
16. Dubocovich M. L., Yun K., Al Ghoul W. M., Benloucif S. & Masana M. I., Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J., 1998, 12, 1211-1220.
17. Dubocovich M. L., Rivera-Bermudez M. A., Gerdin M. J. & Masana M. I., Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci., 2003, 8, d1093-d1108.
18. Dubocovich M. L. & Markowska M., Functional MT1 and MT2 melatonin receptors in mammals. Endocrine, 2005, 27, 101-110.
19. Dubocovich M. L., Hudson R. L., Sumaya I. C., Masana M. I. & Manna E., Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J. Pineal Res., 2005, 39, 113-120.
20. Ekmekcioglu C., Melatonin receptors in humans: biological role and clinical relevance. Biomed. Pharmacother., 2006, 60, 97-108.
21. Fourmaintraux E., Depreux P., Lesieur D., Guardiola-Lemaitre B., Bennejean C., Delagrange P. & Howell H. E., Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors. Bioorg. Med. Chem., 1998, 6, 9-13.
22. Gauer F., Masson-Pévet M. & Pévet P., Melatonin receptor density is regulated in rat pars tuberalis and suprachiasmatic nuclei by melatonin itself. Brain Res., 1993, 602, 153-156.
23. Gauer F., Masson-Pévet M., Stehle J. & Pévet P., Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Res., 1994a, 641, 92-98.
24. Gauer F., Masson-Pévet M. & Pévet P., Seasonal regulation of melatonin receptors in rodent pars tuberalis: correlation with reproductive state. J. Neural Transm. Gen. Sect., 1994b, 96, 187-195.
25. Gauer F., Schuster C., Pévet P. & Masson-Pévet M., Effect of a light pulse on melatonin receptor density and mRNA expression in Siberian hamster suprachiasmatic nuclei. Neurosci. Lett., 1997, 233, 49-52.
26. Gauer F., Schuster C., Poirel V. J., Pévet, P. & Masson-Pévet M., Cloning experiments and developmental expression of both melatonin receptor Mel1A mRNA and melatonin binding sites in the Syrian hamster suprachiasmatic nuclei. Brain Res. Mol. Brain Res., 1998, 60, 193-202.
27. Goldman B. D. & Darrow J. M., The pineal gland and mammalian photoperiodism. Neuroendocrinology, 1983, 37, 386-396.
28. Guardiola-Lemaitre B., Melatoninergic receptor agonists and antagonists: pharmacological aspects and therapeutic perspective. Ann. Pharm. Fr., 2005, 63, 385-400.
29. Guerrero H. Y., Gauer F., Schuster C., Pévet P. & Masson-Pévet M., Melatonin regulates the mRNA expression of the mt(1) melatonin receptor in the rat pars tuberalis. Neuroendocrinology, 2000, 71, 163-169.
30. Hazlerigg D. G., Hastings M. H. & Morgan P. J., Production of a prolactin releasing factor by the ovine pars tuberalis. J. Neuroendocrinol., 1996, 8, 489-492.
31. Hill S. M., Kiefer T., Teplitzky S., Spriggs L. L. & Ram P., Modulation of the estrogen response pathway in human breast cancer cells by melatonin. In : Bartsch C., Bartsch H., Blask D. E., Cardinali D. P., Hrushesky W. J. M, & Mecke D. (Eds) The pineal gland and cancer. Springer-Verlag, Berlin, 2001, 343-358.
32. Jiang Z. G., Nelson C. S. & Allen C. N., Melatonin activates an outward current and inhibits Ih in rat suprachiasmatic nucleus neurons. Brain Res., 1995, 687, 125-132.
33. Kennedy S. H. & Emsley R., Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 2006, 16, 93-100.
34. Klein D. C. & Moore R. Y., Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res., 1979, 174, 245-262.
35. Klosen P., Bienvenu C., Demarteau O., Dardente H., Guerrero H., Pévet P. & Masson-Pévet M., The mt1 melatonin receptor and ROR? receptor are co-localized in specific TSH-immunoreactive cells in the pars tuberalis of the rat pituitary. J. Histochem. Cytochem., 2002, 50, 1647-1657.
36. Kokkola T. & Laitinen J. T., Melatonin receptor genes. Ann. Med., 1998, 30, 88-94.
37. Kokkola T., Foord S. M., Watson M. A., Vakkuri O. & Laitinen J. T., Important amino acids for the function of the human MT1 melatonin receptor. Biochem. Pharmacol., 2003, 65, 1463-1471.
38. Le Gouic S., Atgie C., Viguerie-Bascands N., Hanoun N., Larrouy D., Ambid L., Raimbault S., Ricquier D., Delagrange P., Guardiola-Lemaitre B., Penicaud L. & Casteilla L., Characterization of a melatonin binding site in Siberian hamster brown adipose tissue. Eur. J. Pharmacol., 1997, 339, 271-278.
39. Leclerc V., Fourmaintraux E., Depreux P., Lesieur D., Morgan P., Howell H. E., Renard P., Caignard D. H., Pfeiffer B., Delagrange P., Guardiola-Lemaitre B. & Andrieux J., Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. Bioorg. Med. Chem., 1998, 6, 1875-1887.
40. Lerner A. B., Case J. D., Takahashi Y., Lee T. H. & Mori W., Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Amer. Chem. Soc., 1958, 80, 2587.
41. Lesieur D., Leclerc V., Chavatte P., Marot C., Renard P. & Guardiola-Lemaitre B., Melatonin, a pertinent prototype for therapeutic innovation. Thérapie, 1998, 53, 429-437.
42. Levoye A., Dam J., Ayoub M. A., Guillaume J. L., Couturier C., Delagrange P. & Jockers R., The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J., 2006, 25, 3012-3023.
43. Liebmann P. M., Wolfler A., Felsner P., Hofer D. & Schauenstein K., Melatonin and the immune system. Int. Arch. Allergy Immunol., 1997, 112, 203-211.
44. Lincoln G., Messager S., Andersson H. & Hazlerigg D., Temporal expression of seven clock genes in the suprachiasmatic nucleus and the pars tuberalis of the sheep: evidence for an internal coincidence timer. Proc. Natl. Acad. Sci. USA, 2002, 99, 13890-13895.
45. Lincoln G. A. & Richardson M., Photo-neuroendocrine control of seasonal cycles in body weight, pelage growth and reproduction: lessons from the HPD sheep model. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol., 1998, 119, 283-294.
46. Liu C., Weaver D. R., Jin X., Shearman L. P., Pieschl R. L., Gribkoff V. K. & Reppert S. M., Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron, 1997, 19, 91-102.
47. Loo H., Hale A., D'Haenen H., Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17, 239-47.
48. Mailliet F., Ferry G., Vella F., Thiam K., Delagrange P. & Boutin J. A., Organs from mice deleted for NRH: quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett., 2004, 578, 116-120.
49. Malpaux B., Daveau A., Maurice-Mandon F., Duarte G. & Chemineau P., Evidence that melatonin acts in the premammillary hypothalamic area to control reproduction in the ewe: presence of binding sites and stimulation of luteinizing hormone secretion by in situ microimplant delivery. Endocrinology, 1998, 139, 1508-1516.
50. Masson-Pévet M., George D., Kalsbeek A., Saboureau M., Lakhdar-Ghazal N. & Pévet P., An attempt to correlate brain areas containing melatonin-binding sites with rhythmic functions: a study in five hibernator species. Cell Tissue Res., 1994, 278, 97-106.
51. Masson-Pévet M., Gauer F., Schuster C. & Guerrero H. Y., Photic regulation of mt(1) melatonin receptors and 2-iodomelatonin binding in the rat and Siberian hamster. Biol. Signals Recept., 2000, 9, 188-196.
52. Mazna P., Berka K., Jelinkova I., Balik A., Svoboda P., Obsilova V., Obsil T. & Teisinger J., Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7. Biochem. Biophys. Res. Commun., 2005, 332, 726-734.
53. McArthur A. J., Hunt A. E. & Gillette M. U., Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn. Endocrinology, 1997, 138, 627-634.
54. Messager S., Hazlerigg D. G., Mercer J. G. & Morgan P. J., Photoperiod differentially regulates the expression of Per1 and ICER in the pars tuberalis and the suprachiasmatic nucleus of the Siberian hamster. Eur. J. Neurosci., 2000, 12, 2865-2870.
55. Moore R. Y., Organization and function of a central nervous system circadian oscillator: the suprachiasmatic hypothalamic nucleus. Fed. Proc., 1983, 42, 2783-2789.
56. Morgan P. J., Barrett P., Howell H. E. & Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem. Int., 1994, 24, 101-146.
57. Nosjean O., Ferro M., Cogé F., Beauverger P., Henlin J. M., Lefoulon F., Fauchere J. L., Delagrange P., Canet E. & Boutin J. A., Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
58. Petit L., Lacroix I., De Coopet P., Strosberg A.D. & Jockers R., Differential signaling of human Mel1a and Mel1b melatonin receptors through the cGMP pathway. Biochem. Pharmacol., 1999, 58, 633-639.
59. Pévet P., The role of the pineal gland in the photoperiodic control of reproduction in different hamster species. Reprod. Nutr. Dev., 1988, 28, 443-458.
60. Pitrosky B., Kirsch R., Malan A., Mocaer E. & Pévet P., Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am. J. Physiol., 1999, 277, R812-R828.
61. Poirel V. J., Cailotto C., Streicher D., Pévet P., Masson-Pévet M. & Gauer F., MT1 melatonin receptor mRNA tissular localization by PCR amplification. Neuroendocrinol. Lett., 2003, 24, 33-38.
62. Ralph M. R., Foster R. G., Davis F. C. & Menaker M., Transplanted suprachiasmatic nucleus determines circadian period. Science, 1990, 247, 975-978.
63. Recio J., Pévet P., Miguez J. M. & Masson-Pévet M., Melatonin receptors in the suprachiasmatic nuclei and pars tuberalis of testosterone induced photoresponsive rats. Neurosci. Lett., 1996, 214, 53-56.
64. Recio J., Gauer F., Schuster C., Pévet P. & Masson-Pévet M., Daily and photoperiodic 2-125I-melatonin binding changes in the pars tuberalis of the Syrian hamster (Mesocricetus auratus): effect of constant light exposure and pinealectomy. J. Pineal Res., 1998, 24, 162-167.
65. Redman J., Armstrong S. & Ng K. T., Free-running activity rhythms in the rat: entrainment by melatonin. Science, 1983, 219, 1089-1091.
66. Reppert S. M., Weaver D. R. & Ebisawa T., Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron, 1994, 13, 1177-1185.
67. Reppert S. M., Godson C., Mahle C. D., Weaver D. R., Slaugenhaupt S. A. & Gusella J. F., Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc. Natl. Acad. Sci. USA, 1995a, 92, 8734-8738.
68. Reppert S. M., Weaver D. R., Cassone V. M., Godson C. & Kolakowski L. F. Jr., Melatonin receptors are for the birds: molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron, 1995b, 15, 1003-1015.
69. Roca A. L., Godson C., Weaver D. R. & Reppert S. M., Structure, characterization, and expression of the gene encoding the mouse Mel1a melatonin receptor. Endocrinology, 1996, 137, 3469-3477.
70. Scheer F. A. J. L., Van Montfrans G. A., Van Someren E. J. W., Mairuhu G. & Buijs R. M., Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension, 2004, 43, 192-197.
71. Schuster C., Gauer F., Guerrero H., Lakhdar-Ghazal N., Pévet P. & Masson-Pévet M., Photic regulation of mt1 melatonin receptors in the Siberian hamster pars tuberalis and suprachiasmatic nuclei: involvement of the circadian clock and intergeniculate leaflet. J. Neuroendocrinol., 2000, 12, 207-216.
72. Schuster C., Gauer F., Malan A., Recio J., Pévet P. & Masson-Pévet M., The circadian clock, light/dark cycle and melatonin are differentially involved in the expression of daily and photoperiodic variations in mt(1) melatonin receptors in the Siberian and Syrian hamsters. Neuroendocrinology, 2001, 74, 55-68.
73. Schuster C., Williams L. M., Morris A., Morgan P. J. & Barrett P., The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J. Neuroendocrinol., 2005, 17, 170-178.
74. Shiu S. Y., Li L., Xu J. N., Pang C. S., Wong J. T. & Pang S. F., Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J. Pineal Res., 1999, 27, 183-192.
75. Slaugenhaupt S. A., Roca A. L., Liebert C. B., Altherr M. R., Gusella J. F. & Reppert S. M., Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics, 1995, 27, 355-357.
76. Stankov B. & Fraschini F., High affinity melatonin binding sites in the vertebrate brain. Neuroendocrinology Lett., 1993, 15, 149-164.
77. Tamarkin L., Baird C. J. & Almeida O. F., Melatonin: a coordinating signal for mammalian reproduction? Science, 1985, 227, 714-720.
78. Ting K. N., Dunn W. R., Davies D. J., Sugden D., Delagrange P., Guardiola-Lemaitre B., Scalbert E. & Wilson V. G., Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br. J. Pharmacol., 1997, 122, 1299-1306.
79. Vanecek J., Pavlik A. & Illnerova H., Hypothalamic melatonin receptor sites revealed by autoradiography. Brain Res., 1987, 435, 359-362.
80. Vanecek J., Cellular mechanisms of melatonin action. Physiol. Rev., 1998, 78, 687-721.
81. Weaver D. R., Liu C. & Reppert S. M., Nature's knockout: the Mel1b receptor is not necessary for reproductive and circadian responses to melatonin in Siberian hamsters. Mol. Endocrinol., 1996, 10, 1478-1487.
82. Witt-Enderby P. A., Bennett J., Jarzynka M. J., Firestine S. & Melan M. A., Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci., 2003, 72, 2183-2198.
83. Witt-Enderby P. A., Jarzynka M. J., Krawitt B. J. & Melan M. A., Knock-down of RGS4 and beta tubulin in CHO cells expressing the human MT1 melatonin receptor prevents melatonin-induced receptor desensitization. Life Sci., 2004, 75, 2703-2715.
84. Wurtman R., Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev. Neurother., 2006, 6, 957-964.
85. Zlotos D. P., Recent advances in melatonin receptor ligands. Arch. Pharm. (Weinheim), 2005, 338, 229-247.